Biopharma Deal Benchmarks
Data-driven licensing deal term analysis across oncology, neurology, and all major modalities. Upfronts, milestones, royalties, and deal structures.
Try the CalculatorMarket Overviews
Comprehensive 2026 deal landscape analysis across oncology, neurology, immunology, and metabolic/obesity therapeutic areas.
Oncology Licensing Deal Benchmarks 2026
Comprehensive 2026 oncology licensing deal benchmarks across ADCs, CAR-T, bispecifics, and all clinical stages. Data-driven analysis of upfronts, milestones, and royalties.
Neurology & CNS Licensing Deal Benchmarks 2026
Comprehensive 2026 neurology and CNS licensing deal benchmarks. Alzheimer's, Parkinson's, pain, and psychiatric disorder deal terms analyzed.
Metabolic & Obesity Deal Benchmarks 2026
Comprehensive 2026 metabolic and obesity licensing deal benchmarks. GLP-1 agonists, dual incretins, oral peptides, and MASH deal terms analyzed from 35+ R&D partnerships.
Rare Disease Licensing Deal Benchmarks 2026
Rare disease licensing deals average $4.5B total value at Phase 2 with orphan drug designation. Benchmark upfronts, milestones, and royalties across gene therapy, ERT, and substrate reduction.
Hematology Licensing Deal Benchmarks 2026
Comprehensive 2026 hematology licensing benchmarks. CAR-T, bispecific antibody, and small molecule deal terms across lymphoma, leukemia, and myeloproliferative neoplasms.
Dermatology Licensing Deal Benchmarks 2026
Comprehensive 2026 dermatology licensing benchmarks. IL-17, IL-13, JAK inhibitor, and topical biologic deal terms across atopic dermatitis, psoriasis, and emerging indications.
Gastroenterology Licensing Deal Benchmarks 2026
Comprehensive 2026 gastroenterology licensing benchmarks. Anti-TL1A, IL-23, and S1P modulator deal terms across Crohn's disease, ulcerative colitis, and emerging GI indications.
Immunology & Autoimmune Deal Benchmarks 2026
Immunology licensing deals average $3.0B total value at Phase 2. Benchmark autoimmune deal terms for lupus, JAK inhibitors, and biologics.
Cardiovascular Deal Benchmarks 2026
Cardiovascular licensing deals average $2.4B total value at Phase 2. Benchmark CV deal terms for heart failure, PCSK9, and lipid therapies.
Infectious Disease Deal Benchmarks 2026
Infectious disease licensing deals average $1.9B total value at Phase 2. Benchmark antiviral, antibiotic, and vaccine deal terms.
Ophthalmology Deal Benchmarks 2026
Ophthalmology licensing deals average $2.5B total value at Phase 2. Benchmark gene therapy, anti-VEGF, and retinal deal terms.
ADC vs. Bispecific Antibody Deal Terms Comparison
Compare ADC vs bispecific antibody deal terms: ADC median upfront $393M vs bispecific $348M. Side-by-side benchmarks.
Phase 1 vs. Phase 2 Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms: Phase 1 upfront $90M vs Phase 2 $258M. Data-driven stage comparison.
Oncology vs. Neurology Licensing Deal Comparison
Compare oncology vs neurology deal terms: oncology upfront $258M vs neurology $423M. TA-specific benchmarks.
By Modality
Deal benchmarks segmented by drug modality — ADCs, CAR-T, bispecifics, gene therapy, and more.
ADC Licensing Deal Benchmarks
ADC licensing deals average $2.5B total value with $393M upfront at Phase 2. Explore benchmark deal terms for antibody-drug conjugates.
CAR-T Cell Therapy Deal Benchmarks
CAR-T licensing deals average $1.0B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for hematologic CAR-T cell therapies.
Bispecific Antibody Deal Benchmarks
Bispecific antibody licensing deals average $2.2B total value at Phase 2. Benchmark upfronts, milestones, and royalties for bispecific deals.
Radiopharmaceutical Deal Benchmarks
Radiopharmaceutical deals average $1.5B total value at Phase 1. Explore upfront payments, milestones, and royalty benchmarks for RPT licensing.
Gene Therapy & Gene Editing Deal Benchmarks
Gene therapy licensing deals average $864M total value at Phase 1. Benchmark upfronts, milestones, and royalty rates for gene therapy and gene editing deals.
Small Molecule Licensing Deal Benchmarks
Small molecule licensing deals average $1.6B total value at Phase 2. Comprehensive benchmarks for upfronts, milestones, and royalties.
GLP-1 Agonist Obesity Deal Benchmarks 2026
GLP-1 agonist obesity deals average $4.5B total value at Phase 2. Compare injectable vs oral GLP-1 deal terms, upfronts, milestones, and royalties.
Dual & Triple Incretin Deal Benchmarks 2026
Dual incretin (GLP-1/GIP) deals average $5.5B total value. Compare dual vs triple agonist deal terms and benchmarks.
Oral Peptide & Oral GLP-1 Deal Benchmarks 2026
Oral peptide obesity deals average $5.1B total value — 20-30% premium over injectables. Benchmark oral GLP-1 deal terms.
Gene Therapy Rare Disease Deal Benchmarks
Gene therapy rare disease deals average $2.3B total value at Phase 1. Benchmark upfronts, milestones, and royalties for orphan gene therapy licensing.
Enzyme Replacement Therapy Deal Benchmarks
ERT licensing deals average $3.1B total value at Phase 2. Benchmark deal terms for enzyme replacement therapies targeting Fabry, Gaucher, and Pompe disease.
CAR-T Hematology Deal Benchmarks
CAR-T hematology deals average $2.1B total value at Phase 1. Benchmark upfronts, milestones, and royalties for hematologic CAR-T cell therapy licensing.
Bispecific Antibody Hematology Deal Benchmarks
Bispecific antibody hematology deals average $3.6B total value at Phase 2. Benchmark deal terms for hematologic bispecific antibody licensing.
IL-17 Inhibitor Deal Benchmarks
IL-17 inhibitor licensing deals average $2.1B total value at Phase 2. Benchmark upfronts, milestones, and royalties for IL-17 pathway deals.
JAK Inhibitor Dermatology Deal Benchmarks
JAK inhibitor dermatology deals average $2.0B total value at Phase 2. Benchmark deal terms for JAK inhibitors in atopic dermatitis, alopecia areata, and vitiligo.
Anti-TL1A Deal Benchmarks
Anti-TL1A licensing deals average $3.3B total value at Phase 2. Benchmark deal terms for TL1A-targeting therapies in Crohn's disease and ulcerative colitis.
IL-23 GI Deal Benchmarks
IL-23 inhibitor GI deals average $3.0B total value at Phase 2. Benchmark deal terms for IL-23 targeting therapies in ulcerative colitis and Crohn's disease.
Checkpoint Inhibitor (PD-1/PD-L1) Deal Benchmarks
Checkpoint inhibitor licensing deals average $1.7B total value at Phase 2. Benchmark PD-1/PD-L1 IO deal terms, milestones, and royalties.
RNAi & siRNA Licensing Deal Benchmarks
RNAi/siRNA licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for RNA interference therapeutics.
PROTAC & Targeted Protein Degrader Deal Benchmarks
PROTAC/degrader licensing deals average $1.0B total value at Phase 1. Benchmark upfronts, milestones, and royalties for targeted protein degradation deals.
mRNA Therapeutics Deal Benchmarks
mRNA therapeutics licensing deals average $2.5B total value at Phase 2. Benchmark upfronts, milestones, and royalties for mRNA platform deals.
Monoclonal Antibody (mAb) Licensing Deal Benchmarks
Monoclonal antibody licensing deals average $2.5B total value at Phase 2. Benchmark upfronts, milestones, and royalties for mAb deals.
Cell Therapy Deal Benchmarks (Beyond CAR-T)
Non-CAR-T cell therapy deals average $1.0B total value at Phase 1. Benchmark upfronts, milestones, and royalties for TIL, NK cell, and iPSC-derived therapies.
Precision Oncology & Biomarker-Driven Deal Benchmarks
Biomarker-selected oncology deals average $1.9B total value at Phase 2. Benchmark upfronts, milestones, and royalties for precision medicine deals.
Obesity & Weight Loss Drug Deal Benchmarks 2026
Obesity/weight loss drug deals average $7.5B total value at Phase 3. Benchmark upfronts, milestones, and royalties for GLP-1 agonist licensing.
Autoimmune Biologics Deal Benchmarks
Autoimmune biologics licensing deals average $3.0B total value at Phase 2. Benchmark upfronts, milestones, and royalties for autoimmune biologic deals.
Rare Disease Gene Therapy Deal Benchmarks 2026
Rare disease gene therapy deals average $2.2B total value at Phase 1 in 2026. Updated benchmarks for orphan gene therapy upfronts, milestones, and royalties.
Approved Drug Licensing & Out-Licensing Deal Benchmarks
Approved drug licensing deals average $5.7B total value. Benchmark upfronts, milestones, and royalties for marketed product out-licensing deals.
By Indication
Deal benchmarks for specific disease indications — NSCLC, breast cancer, myeloma, and Alzheimer's.
Lung Cancer (NSCLC) Licensing Deal Benchmarks
NSCLC licensing deals average $1.6B total value at Phase 2. Benchmark deal terms for non-small cell lung cancer licensing agreements.
Breast Cancer (TNBC) Licensing Deal Benchmarks
TNBC licensing deals average $2.5B total value at Phase 2. Benchmark upfronts, milestones, and royalties for triple-negative breast cancer deals.
Alzheimer's Disease Licensing Deal Benchmarks
Alzheimer's licensing deals average $3.5B total value at Phase 2. Benchmark deal terms for Alzheimer's disease-modifying and symptomatic therapies.
Multiple Myeloma Licensing Deal Benchmarks
Multiple myeloma licensing deals average $2.4B total value at Phase 2. Benchmark upfronts, milestones, and royalties for myeloma deals.
NASH/MASH Deal Benchmarks 2026
NASH/MASH licensing deals average $3.1B total value. Benchmark deal terms for steatohepatitis therapies following resmetirom approval.
Parkinson's Disease Licensing Deal Benchmarks
Parkinson's disease licensing deals average $3.1B total value at Phase 2. Benchmark PD deal terms, milestones, and royalties.
By Clinical Stage
Deal benchmarks across development stages — preclinical, Phase 2, and Phase 3 licensing terms.
Preclinical Licensing Deal Benchmarks
Preclinical licensing deals average $504M total value. Benchmark upfronts, milestones, and royalties for IND-enabling stage assets.
Phase 2 Licensing Deal Benchmarks
Phase 2 licensing deals average $1.6B total value. Comprehensive benchmarks for upfronts, milestones, and royalties at the proof-of-concept stage.
Phase 3 Licensing Deal Benchmarks
Phase 3 licensing deals average $3.1B total value with $721M upfront. Benchmark deal terms for pivotal-stage assets.
Model Your Own Deal Terms
Use our calculator to customize inputs for your specific asset — phase, modality, indication, competitive position, and more — and get instant deal term estimates.
Start Calculating